Research ExplorerPublicationsOutcomes of Redo Transcatheter Aortic Valve Replacement Acco...

Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type

Standard

Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. / Landes, Uri; Richter, Ilan; Danenberg, Haim; Kornowski, Ran; Sathananthan, Janarthanan; De Backer, Ole; Søndergaard, Lars; Abdel-Wahab, Mohamed; Yoon, Sung-Han; Makkar, Raj R; Thiele, Holger; Kim, Won-Keun; Hamm, Christian; Buzzatti, Nicola; Montorfano, Matteo; Ludwig, Sebastian; Schofer, Niklas; Voigtlaender, Lisa; Guerrero, Mayra; El Sabbagh, Abdallah; Rodés-Cabau, Josep; Mesnier, Jules; Okuno, Taishi; Pilgrim, Thomas; Fiorina, Claudia; Colombo, Antonio; Mangieri, Antonio; Eltchaninoff, Helene; Nombela-Franco, Luis; Van Wiechen, Maarten P H; Van Mieghem, Nicolas M; Tchétché, Didier; Schoels, Wolfgang H; Kullmer, Matthias; Barbanti, Marco; Tamburino, Corrado; Sinning, Jan-Malte; Al-Kassou, Baravan; Perlman, Gidon Y; Ielasi, Alfonso; Fraccaro, Chiara; Tarantini, Giuseppe; De Marco, Federico; Witberg, Guy; Redwood, Simon R; Lisko, John C; Babaliaros, Vasilis C; Laine, Mika; Nerla, Roberto; Finkelstein, Ariel; Eitan, Amnon; Jaffe, Ronen; Ruile, Philipp; Neumann, Franz J; Piazza, Nicolo; Sievert, Horst; Sievert, Kolja; Russo, Marco; Andreas, Martin; Bunc, Matjaz; Latib, Azeem; Bruoha, Sharon; Godfrey, Rebecca; Hildick-Smith, David; Barbash, Israel; Segev, Amit; Maurovich-Horvat, Pál; Szilveszter, Balint; Spargias, Konstantinos; Aravadinos, Dionisis; Nazif, Tamim M; Leon, Martin B; Webb, John G; Redo-TAVR Registry.

In: JACC-CARDIOVASC INTE, Vol. 15, No. 15, 08.08.2022, p. 1543-1554.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Landes, U, Richter, I, Danenberg, H, Kornowski, R, Sathananthan, J, De Backer, O, Søndergaard, L, Abdel-Wahab, M, Yoon, S-H, Makkar, RR, Thiele, H, Kim, W-K, Hamm, C, Buzzatti, N, Montorfano, M, Ludwig, S, Schofer, N, Voigtlaender, L, Guerrero, M, El Sabbagh, A, Rodés-Cabau, J, Mesnier, J, Okuno, T, Pilgrim, T, Fiorina, C, Colombo, A, Mangieri, A, Eltchaninoff, H, Nombela-Franco, L, Van Wiechen, MPH, Van Mieghem, NM, Tchétché, D, Schoels, WH, Kullmer, M, Barbanti, M, Tamburino, C, Sinning, J-M, Al-Kassou, B, Perlman, GY, Ielasi, A, Fraccaro, C, Tarantini, G, De Marco, F, Witberg, G, Redwood, SR, Lisko, JC, Babaliaros, VC, Laine, M, Nerla, R, Finkelstein, A, Eitan, A, Jaffe, R, Ruile, P, Neumann, FJ, Piazza, N, Sievert, H, Sievert, K, Russo, M, Andreas, M, Bunc, M, Latib, A, Bruoha, S, Godfrey, R, Hildick-Smith, D, Barbash, I, Segev, A, Maurovich-Horvat, P, Szilveszter, B, Spargias, K, Aravadinos, D, Nazif, TM, Leon, MB, Webb, JG & Redo-TAVR Registry 2022, 'Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type', JACC-CARDIOVASC INTE, vol. 15, no. 15, pp. 1543-1554. https://doi.org/10.1016/j.jcin.2022.05.016

APA

Landes, U., Richter, I., Danenberg, H., Kornowski, R., Sathananthan, J., De Backer, O., Søndergaard, L., Abdel-Wahab, M., Yoon, S-H., Makkar, R. R., Thiele, H., Kim, W-K., Hamm, C., Buzzatti, N., Montorfano, M., Ludwig, S., Schofer, N., Voigtlaender, L., Guerrero, M., ... Redo-TAVR Registry (2022). Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. JACC-CARDIOVASC INTE, 15(15), 1543-1554. https://doi.org/10.1016/j.jcin.2022.05.016

Vancouver

Landes U, Richter I, Danenberg H, Kornowski R, Sathananthan J, De Backer O et al. Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. JACC-CARDIOVASC INTE. 2022 Aug 8;15(15):1543-1554. https://doi.org/10.1016/j.jcin.2022.05.016

Bibtex

@article{4023002408aa4801803f8bee27d7584b,
title = "Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type",
abstract = "BACKGROUND: As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV (sTAV) potentially affects TAV-in-TAV outcome.OBJECTIVES: The purpose of this study was to better inform prosthesis selection, TAV-in-TAV outcomes were assessed according to the type of initial and subsequent TAV.METHODS: Patients from the Redo-TAVR registry were analyzed using propensity weighting according to their initial valve type (bTAV [n = 115] vs sTAV [n = 106]) and subsequent valve type (bTAV [n = 130] vs sTAV [n = 91]).RESULTS: Patients with failed bTAVs presented later (vs sTAV) (4.9 ± 2.1 years vs 3.7 ± 2.3 years; P < 0.001), with smaller effective orifice area (1.0 ± 0.7 cm2 vs 1.3 ± 0.8 cm2; P = 0.018) and less frequent dominant regurgitation (16.2% vs 47.3%; P < 0.001). Mortality at 30 days was 2.3% (TAV-in-bTAV) vs 0% (TAV-in-sTAV) (P = 0.499) and 1.7% (bTAV-in-TAV) vs 1.0% (sTAV-in-TAV) (P = 0.612); procedural safety was 72.6% (TAV-in-bTAV) vs 71.2% (TAV-in-sTAV) (P = 0.817) and 73.2% (bTAV-in-TAV) vs 76.5% (sTAV-in-TAV) (P = 0.590). Device success was similar according to initial valve type but higher with subsequent sTAV vs bTAV (77.2% vs 64.3%; P = 0.045), primarily because of lower residual gradients (10.3 mm Hg [8.9-11.7 mm Hg] vs 15.2 mm Hg [13.2-17.1 mm Hg]; P < 0.001). Residual regurgitation (moderate or greater) was similar after bTAV-in-TAV and sTAV-in-TAV (5.7%) and nominally higher after TAV-in-bTAV (9.1%) vs TAV-in-sTAV (4.4%) (P = 0.176).CONCLUSIONS: In selected patients, no association was observed between TAV type and redo TAVR safety or mortality, yet subsequent sTAV was associated with higher device success because of lower redo gradients. These findings are preliminary, and more data are needed to guide valve choice for redo TAVR.",
keywords = "Aortic Valve/diagnostic imaging, Aortic Valve Stenosis/diagnostic imaging, Heart Valve Prosthesis, Humans, Prosthesis Design, Registries, Risk Factors, Transcatheter Aortic Valve Replacement, Treatment Outcome",
author = "Uri Landes and Ilan Richter and Haim Danenberg and Ran Kornowski and Janarthanan Sathananthan and {De Backer}, Ole and Lars S{\o}ndergaard and Mohamed Abdel-Wahab and Sung-Han Yoon and Makkar, {Raj R} and Holger Thiele and Won-Keun Kim and Christian Hamm and Nicola Buzzatti and Matteo Montorfano and Sebastian Ludwig and Niklas Schofer and Lisa Voigtlaender and Mayra Guerrero and {El Sabbagh}, Abdallah and Josep Rod{\'e}s-Cabau and Jules Mesnier and Taishi Okuno and Thomas Pilgrim and Claudia Fiorina and Antonio Colombo and Antonio Mangieri and Helene Eltchaninoff and Luis Nombela-Franco and {Van Wiechen}, {Maarten P H} and {Van Mieghem}, {Nicolas M} and Didier Tch{\'e}tch{\'e} and Schoels, {Wolfgang H} and Matthias Kullmer and Marco Barbanti and Corrado Tamburino and Jan-Malte Sinning and Baravan Al-Kassou and Perlman, {Gidon Y} and Alfonso Ielasi and Chiara Fraccaro and Giuseppe Tarantini and {De Marco}, Federico and Guy Witberg and Redwood, {Simon R} and Lisko, {John C} and Babaliaros, {Vasilis C} and Mika Laine and Roberto Nerla and Ariel Finkelstein and Amnon Eitan and Ronen Jaffe and Philipp Ruile and Neumann, {Franz J} and Nicolo Piazza and Horst Sievert and Kolja Sievert and Marco Russo and Martin Andreas and Matjaz Bunc and Azeem Latib and Sharon Bruoha and Rebecca Godfrey and David Hildick-Smith and Israel Barbash and Amit Segev and P{\'a}l Maurovich-Horvat and Balint Szilveszter and Konstantinos Spargias and Dionisis Aravadinos and Nazif, {Tamim M} and Leon, {Martin B} and Webb, {John G} and {Redo-TAVR Registry}",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",
year = "2022",
month = aug,
day = "8",
doi = "10.1016/j.jcin.2022.05.016",
language = "English",
volume = "15",
pages = "1543--1554",
journal = "JACC-CARDIOVASC INTE",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "15",

}

RIS

TY - JOUR

T1 - Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type

AU - Landes, Uri

AU - Richter, Ilan

AU - Danenberg, Haim

AU - Kornowski, Ran

AU - Sathananthan, Janarthanan

AU - De Backer, Ole

AU - Søndergaard, Lars

AU - Abdel-Wahab, Mohamed

AU - Yoon, Sung-Han

AU - Makkar, Raj R

AU - Thiele, Holger

AU - Kim, Won-Keun

AU - Hamm, Christian

AU - Buzzatti, Nicola

AU - Montorfano, Matteo

AU - Ludwig, Sebastian

AU - Schofer, Niklas

AU - Voigtlaender, Lisa

AU - Guerrero, Mayra

AU - El Sabbagh, Abdallah

AU - Rodés-Cabau, Josep

AU - Mesnier, Jules

AU - Okuno, Taishi

AU - Pilgrim, Thomas

AU - Fiorina, Claudia

AU - Colombo, Antonio

AU - Mangieri, Antonio

AU - Eltchaninoff, Helene

AU - Nombela-Franco, Luis

AU - Van Wiechen, Maarten P H

AU - Van Mieghem, Nicolas M

AU - Tchétché, Didier

AU - Schoels, Wolfgang H

AU - Kullmer, Matthias

AU - Barbanti, Marco

AU - Tamburino, Corrado

AU - Sinning, Jan-Malte

AU - Al-Kassou, Baravan

AU - Perlman, Gidon Y

AU - Ielasi, Alfonso

AU - Fraccaro, Chiara

AU - Tarantini, Giuseppe

AU - De Marco, Federico

AU - Witberg, Guy

AU - Redwood, Simon R

AU - Lisko, John C

AU - Babaliaros, Vasilis C

AU - Laine, Mika

AU - Nerla, Roberto

AU - Finkelstein, Ariel

AU - Eitan, Amnon

AU - Jaffe, Ronen

AU - Ruile, Philipp

AU - Neumann, Franz J

AU - Piazza, Nicolo

AU - Sievert, Horst

AU - Sievert, Kolja

AU - Russo, Marco

AU - Andreas, Martin

AU - Bunc, Matjaz

AU - Latib, Azeem

AU - Bruoha, Sharon

AU - Godfrey, Rebecca

AU - Hildick-Smith, David

AU - Barbash, Israel

AU - Segev, Amit

AU - Maurovich-Horvat, Pál

AU - Szilveszter, Balint

AU - Spargias, Konstantinos

AU - Aravadinos, Dionisis

AU - Nazif, Tamim M

AU - Leon, Martin B

AU - Webb, John G

AU - Redo-TAVR Registry

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2022/8/8

Y1 - 2022/8/8

N2 - BACKGROUND: As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV (sTAV) potentially affects TAV-in-TAV outcome.OBJECTIVES: The purpose of this study was to better inform prosthesis selection, TAV-in-TAV outcomes were assessed according to the type of initial and subsequent TAV.METHODS: Patients from the Redo-TAVR registry were analyzed using propensity weighting according to their initial valve type (bTAV [n = 115] vs sTAV [n = 106]) and subsequent valve type (bTAV [n = 130] vs sTAV [n = 91]).RESULTS: Patients with failed bTAVs presented later (vs sTAV) (4.9 ± 2.1 years vs 3.7 ± 2.3 years; P < 0.001), with smaller effective orifice area (1.0 ± 0.7 cm2 vs 1.3 ± 0.8 cm2; P = 0.018) and less frequent dominant regurgitation (16.2% vs 47.3%; P < 0.001). Mortality at 30 days was 2.3% (TAV-in-bTAV) vs 0% (TAV-in-sTAV) (P = 0.499) and 1.7% (bTAV-in-TAV) vs 1.0% (sTAV-in-TAV) (P = 0.612); procedural safety was 72.6% (TAV-in-bTAV) vs 71.2% (TAV-in-sTAV) (P = 0.817) and 73.2% (bTAV-in-TAV) vs 76.5% (sTAV-in-TAV) (P = 0.590). Device success was similar according to initial valve type but higher with subsequent sTAV vs bTAV (77.2% vs 64.3%; P = 0.045), primarily because of lower residual gradients (10.3 mm Hg [8.9-11.7 mm Hg] vs 15.2 mm Hg [13.2-17.1 mm Hg]; P < 0.001). Residual regurgitation (moderate or greater) was similar after bTAV-in-TAV and sTAV-in-TAV (5.7%) and nominally higher after TAV-in-bTAV (9.1%) vs TAV-in-sTAV (4.4%) (P = 0.176).CONCLUSIONS: In selected patients, no association was observed between TAV type and redo TAVR safety or mortality, yet subsequent sTAV was associated with higher device success because of lower redo gradients. These findings are preliminary, and more data are needed to guide valve choice for redo TAVR.

AB - BACKGROUND: As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV (sTAV) potentially affects TAV-in-TAV outcome.OBJECTIVES: The purpose of this study was to better inform prosthesis selection, TAV-in-TAV outcomes were assessed according to the type of initial and subsequent TAV.METHODS: Patients from the Redo-TAVR registry were analyzed using propensity weighting according to their initial valve type (bTAV [n = 115] vs sTAV [n = 106]) and subsequent valve type (bTAV [n = 130] vs sTAV [n = 91]).RESULTS: Patients with failed bTAVs presented later (vs sTAV) (4.9 ± 2.1 years vs 3.7 ± 2.3 years; P < 0.001), with smaller effective orifice area (1.0 ± 0.7 cm2 vs 1.3 ± 0.8 cm2; P = 0.018) and less frequent dominant regurgitation (16.2% vs 47.3%; P < 0.001). Mortality at 30 days was 2.3% (TAV-in-bTAV) vs 0% (TAV-in-sTAV) (P = 0.499) and 1.7% (bTAV-in-TAV) vs 1.0% (sTAV-in-TAV) (P = 0.612); procedural safety was 72.6% (TAV-in-bTAV) vs 71.2% (TAV-in-sTAV) (P = 0.817) and 73.2% (bTAV-in-TAV) vs 76.5% (sTAV-in-TAV) (P = 0.590). Device success was similar according to initial valve type but higher with subsequent sTAV vs bTAV (77.2% vs 64.3%; P = 0.045), primarily because of lower residual gradients (10.3 mm Hg [8.9-11.7 mm Hg] vs 15.2 mm Hg [13.2-17.1 mm Hg]; P < 0.001). Residual regurgitation (moderate or greater) was similar after bTAV-in-TAV and sTAV-in-TAV (5.7%) and nominally higher after TAV-in-bTAV (9.1%) vs TAV-in-sTAV (4.4%) (P = 0.176).CONCLUSIONS: In selected patients, no association was observed between TAV type and redo TAVR safety or mortality, yet subsequent sTAV was associated with higher device success because of lower redo gradients. These findings are preliminary, and more data are needed to guide valve choice for redo TAVR.

KW - Aortic Valve/diagnostic imaging

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Heart Valve Prosthesis

KW - Humans

KW - Prosthesis Design

KW - Registries

KW - Risk Factors

KW - Transcatheter Aortic Valve Replacement

KW - Treatment Outcome

U2 - 10.1016/j.jcin.2022.05.016

DO - 10.1016/j.jcin.2022.05.016

M3 - SCORING: Journal article

C2 - 35926921

VL - 15

SP - 1543

EP - 1554

JO - JACC-CARDIOVASC INTE

JF - JACC-CARDIOVASC INTE

SN - 1936-8798

IS - 15

ER -